
Introduction Mycobacteria are typically identified using the acid-fast staining technique. Prior reports have observed cross-reactivity of Treponema pallidum immunohistochemistry (IHC) with Mycobacterium species, particularly Mycobacterium leprae. Further characterization of this cross-reactivity is needed across a broader range of Mycobacterium species, including its extent, strength, and quality.Materials and Methods A retrospective review was conducted to identify all cases of mycobacterial infection at a single institution. Cases with available histopathologic slides were included. Cases in which mycobacteria were not identified on histologic examination were excluded. T. pallidum IHC was performed for each case that met inclusion criteria, and staining patterns were recorded.Results Of the 55 cases of mycobacterial infection identified, a total of 19 cases met the inclusion criteria: 10 cases of M. leprae, 6 cases of M. chelonae, 2 cases of M. tuberculosis, and 1 case of M. avium. IHC for T. pallidum showed cross-reactivity in all 10 M. leprae cases (100%), 3 of 6 M. chelonae cases (50%), 1 of 2 M. tuberculosis cases (50%), and no staining in the single M. avium case. Cases of M. leprae and M. chelonae showed a consistent strong granular and clumped staining pattern.Conclusions This study demonstrates that T. pallidum IHC can highlight diverse Mycobacterium species, a cross-reactivity that pathologists should recognize to avoid false-positive interpretations. In the appropriate clinical context, this cross-reactivity may be utilized to further support the diagnosis of leprosy, given the consistently strong staining observed with M. leprae.
ABSTRACT Aims Cellular neurothekeoma (cNTK) is a benign cutaneous tumor of uncertain histogenesis. Recent genomic characterization identified recurrent deletions on chromosome 9p21.3, encompassing CDKN2A (p16), as a primary driver event in cNTK. We assessed the potential utility of p16 and MTAP immunohistochemistry for discriminating cNTKs from morphologic mimics. Methods and Results Immunohistochemistry for p16 and MTAP was performed on 21 and 19 cNTKs, respectively, and a broad comparison group of fibrohistiocytic neoplasms. Staining distribution was scored semi‐quantitatively. Low/absent p16 expression (Score 1) was observed in 17 of 21 (81%) cNTK cases. Low/absent p16 was significantly more likely in cNTK relative to atypical fibrous histiocytoma, dermatofibroma, Langerhans cell histiocytosis, and pleomorphic dermal sarcoma. However, there was no statistical difference relative to some other tumor types, including plexiform fibrohistiocytic tumor or atypical fibroxanthoma. Only 26% of assessed cNTK cases (5/19) showed loss of MTAP; this did not reach statistical significance relative to other tumor types. Conclusions Low/absent p16 expression is common in cNTKs, corroborating recent genetic evidence for 9p21.3 deletion. Diagnostic utility of low/absent p16 varied, with high specificity in comparison to atypical fibrous histiocytoma and low utility for plexiform fibrohistiocytic tumor. Despite its proximity to CDKN2A on 9p21.3, MTAP immunohistochemistry shows low sensitivity for cNTKs, with diminished staining in only a small subset of tumors. Our findings suggest that low/absent p16 can be diagnostically informative for cNTK in certain contexts; however, low specificity against some tumor types is an important limitation.
ABSTRACT Histiocytoid Sweet syndrome (H‐SS) is a variant of Sweet syndrome characterized by a dermal infiltrate of immature myeloid cells with histiocytoid morphology rather than mature neutrophils. These cells express myeloid markers including myeloperoxidase, lysozyme, CD15, and CD13. H‐SS has been associated with hematologic malignancies and demonstrates higher relapse rates compared with classic Sweet syndrome. This review synthesizes current evidence on the clinicopathologic features, immunophenotype, disease associations, and treatment of H‐SS, and examines its position within the broader spectrum of myeloid cutaneous infiltrates.
Background Dermal postinflammatory hyperpigmentation (PIH) is frequently refractory to treatment, and therapeutic response is thought to depend on the depth and distribution of dermal pigment. Key quantitative histopathologic features, however, remain poorly defined.Methods Ninety-five biopsy-proven cases of dermal PIH were analyzed. Fontana-Masson-stained sections underwent image analysis to quantify epidermal and dermal pigmentation intensity, melanophage density, cross-sectional area, and depth. Associations with inflammatory etiology, Fitzpatrick skin type (FST), and sun-exposure status of the biopsy site were assessed.Results Epidermal pigmentation intensity was significantly increased in spongiotic dermatitis, higher FST, and sun-exposed sites. Dermal pigmentation intensity was associated with sun exposure. Melanophage density increased with higher FST but was lower in spongiotic dermatitis compared with lichenoid and vacuolar interface dermatitis. In contrast, melanophage cross-sectional area and depth showed no significant associations with etiology, FST, or anatomic site. Median melanophage depth was 295.0 mu m (IQR, 220.0-407.0 mu m) from stratum corneum and 163.0 mu m (IQR, 111.2-235.5 mu m) from basement membrane, with consistent measurements across subgroups.Conclusion Despite variability in epidermal pigmentation and melanophage density, melanophage depth is uniform across dermal PIH. These findings refine the conventional epidermal-dermal PIH classification and support a quantitative, anatomy-based framework to inform depth-targeted treatment strategies.